1.79
+0.06(+3.47%)
Currency In USD
| Previous Close | 1.73 |
| Open | 1.74 |
| Day High | 1.79 |
| Day Low | 1.69 |
| 52-Week High | 3.19 |
| 52-Week Low | 1.41 |
| Volume | 459,295 |
| Average Volume | 436,904 |
| Market Cap | 64.35M |
| PE | -3.03 |
| EPS | -0.59 |
| Moving Average 50 Days | 1.68 |
| Moving Average 200 Days | 1.9 |
| Change | 0.06 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $146.72 as of September 29, 2025 at a share price of $1.79. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $564.67 as of September 29, 2025 at a share price of $1.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
GlobeNewswire Inc.
Sep 23, 2025 11:40 AM GMT
BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric, small-molecule t
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
GlobeNewswire Inc.
Sep 18, 2025 11:41 AM GMT
Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule The Phase 1b study enrolled 21 subjects and the last participants will complete 9
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
GlobeNewswire Inc.
Sep 04, 2025 12:00 PM GMT
Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) met recently and recommended to continue the study w